What we cover

Metabolic

Metabolic change is the slowest-moving and most reversible-looking thing we cover, which makes the measurement gap here particularly costly. By the time a standard panel flags a problem, the process producing it has usually been running for years.

What this beat covers

The distinction between what a system is producing and how hard it is working to produce it. Fasting glucose reports the output. Fasting insulin reports the effort. A normal glucose held up by steadily rising insulin is a different situation from a normal glucose that needs no help, and only one of the two is visible on a routine panel.

We also cover the ratios and derived measures that carry more information than any single value — triglyceride to HDL, calculated insulin resistance indices — and the practical question of which of them a reader can get ordered.

Why the timing matters here

Most of what we write about is measured to establish a baseline. Metabolic markers are different: they are measured to catch a trajectory while it is still cheap to change. The interval between "insulin drifting" and "glucose abnormal" is often years, and it is the part of the curve where behaviour still moves the numbers substantially.

That is also why single readings matter less here than in any other beat. One fasting insulin is close to meaningless. Three, taken the same way over three years, is a direction.

The measures

What we write about in this area

Fasting insulin: Moves years before fasting glucose does, because the pancreas compensates to hold glucose steady.
HbA1c: A three-month average, useful precisely because it is harder to game with one careful week.
Triglyceride to HDL ratio: Derived from values almost every panel already contains, and frequently more informative than either alone.
Liver enzymes and liver fat: Where metabolic change often shows up first, and where it is routinely noted and not followed up.
Resting metabolic rate: Measured rather than estimated from a formula built on population averages.

Questions we keep coming back to

How early is too early to start tracking fasting insulin?
What does continuous glucose monitoring add for someone who is not diabetic, and what does it just add noise to?
Which derived indices are worth the arithmetic and which are marketing?

We work through these continuously. The Coastline Brief is where the answers land first.